| Type | Title | Date Released | |
|---|---|---|---|
8-K | Liminatus Pharma Enters into Private Placement Agreement for $650,002.50 | ||
8-K | Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule | ||
8-K | Liminatus Pharma, Inc. Announces 1-for-50 Reverse Stock Split | ||
10-Q | Form 10-Q | ||
8-K | Liminatus Pharma, Inc. Announces Results of 2026 Annual Meeting of Stockholders | ||
8-K | Liminatus Pharma, Inc. Reports Stockholders’ Equity Exceeding Nasdaq Compliance Threshold Following Merger | ||
8-K | Liminatus Pharma Faces Potential Nasdaq Delisting Following Bid Price Deficiency | ||
SCHEDULE 13G | Samda Biolab Co., Ltd. (Filed by) | ||
4 | Kim Chris (Reporting) | ||
SCHEDULE 13D/A | Valetudo Therapeutics LLC (Filed by) | ||
DEF 14A | Form DEF 14A | ||
4 | Kim Chris (Reporting) |
